IDX320: Phase I start

This quarter, Idenix will begin a double-blind, placebo-controlled, European Phase I trial to evaluate single and multiple doses of oral IDX320 in healthy volunteers. Novartis AG (NYSE:NVS; SIX:NOVN,...